Establishment Labs (NASDAQ:ESTA) Price Target Raised to $70.00

Establishment Labs (NASDAQ:ESTA - Free Report) had its target price upped by Mizuho from $58.00 to $70.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other brokerages have also recently commented on ESTA. Wall Street Zen cut shares of Establishment Labs from a "hold" rating to a "sell" rating in a research report on Saturday, July 12th. Citigroup upped their price target on shares of Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a research report on Wednesday, July 9th. BTIG Research initiated coverage on shares of Establishment Labs in a research report on Friday, May 16th. They set a "buy" rating and a $62.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $48.00 price target on shares of Establishment Labs in a research report on Friday, June 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $54.83.

Establishment Labs Price Performance

Shares of NASDAQ ESTA traded up $0.90 during midday trading on Wednesday, reaching $43.35. 90,344 shares of the company were exchanged, compared to its average volume of 473,899. The stock's 50-day moving average price is $39.04 and its 200-day moving average price is $36.93. The stock has a market cap of $1.25 billion, a P/E ratio of -13.93 and a beta of 0.80. Establishment Labs has a one year low of $26.56 and a one year high of $50.85. The company has a quick ratio of 2.05, a current ratio of 3.36 and a debt-to-equity ratio of 5.72.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.13. Establishment Labs had a negative net margin of 52.34% and a negative return on equity of 196.25%. The company had revenue of $41.38 million for the quarter, compared to analysts' expectations of $41.15 million. During the same quarter in the previous year, the firm posted ($0.58) earnings per share. Establishment Labs's revenue for the quarter was up 11.3% on a year-over-year basis. On average, sell-side analysts anticipate that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Brown Advisory Inc. grew its position in Establishment Labs by 23.1% in the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock worth $107,729,000 after acquiring an additional 438,057 shares in the last quarter. Capital Research Global Investors grew its position in Establishment Labs by 29.3% in the fourth quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock worth $88,064,000 after acquiring an additional 433,484 shares in the last quarter. Nantahala Capital Management LLC grew its position in Establishment Labs by 7.2% in the first quarter. Nantahala Capital Management LLC now owns 1,774,044 shares of the company's stock worth $72,390,000 after acquiring an additional 119,574 shares in the last quarter. Findell Capital Management LLC grew its position in Establishment Labs by 28.5% in the fourth quarter. Findell Capital Management LLC now owns 1,346,480 shares of the company's stock worth $62,032,000 after acquiring an additional 298,380 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its position in Establishment Labs by 7.4% in the first quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company's stock worth $33,763,000 after acquiring an additional 56,756 shares in the last quarter. 72.91% of the stock is owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.